Francis Ayuk
University Medical Center Hamburg-Eppendorf, Department of Stem Cell Transplantation
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Francis Ayuk as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:03 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05675319 · Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line TherapyUniversitätsklinikum Hamburg-Eppendorf · terminated · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:03 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:03 UTC. The ranking covers the 200 most relevant of 25 PubMed records, and a shared surname and initials can bring in a namesake. All 25 on PubMed
- Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.N Engl J Med · 2016495 citationsRCR 18.6
- 153 citationsRCR 3.4
- 83 citationsRCR 2.0
- Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.Exp Hematol · 201377 citationsRCR 2.1
- Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.Biol Blood Marrow Transplant · 200476 citationsRCR 1.7
- Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).Bone Marrow Transplant · 200674 citationsRCR 1.9
- Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.Br J Haematol · 201274 citationsRCR 2.2
- Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.Exp Hematol · 200659 citationsRCR 1.3
- 51 citationsRCR 2.4
- Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD.Blood Adv · 201947 citationsRCR 2.7